![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Answering these questions can help differentiate transactional vendor relationships from strategic partnerships that add value.
The Pros and Cons of the "Buy and Bill" Model
Leaders chime in on the benefits of the "buy and bill" model.
By
Date
January 26, 2022
By: MedSurg Editorial Team
Read time: 5 minutes
An alternative to the traditional "buy and bill" model of pharmaceutical distribution is bagging, which removes the financial burden from the provider because the specialty pharmacy or third-party payer must purchase the drug before it arrives in the provider's office. McKesson health systems leaders, Barbara Giacomelli and Valerie Russo provide insight on the benefits of the "buy and bill" model, and how to determine what's appropriate for your business.
Related Stories
The most downloaded content by health system pharmacy leaders in October 2025.
Take another opportunity to recognize and celebrate the impactful work of pharmacists as October comes to a close.
McKesson’s Intrafusion expert discusses the measurable impacts of a successful infusion service line in health systems.
Connect with our experts and industry leaders to uncover strategies to help you achieve more.
Join us in taking this opportunity to celebrate the contributions of pharmacy technicians, whose training and professionalism support positive outcomes.
McKesson leaders attending a C-Suite dialogue on leveraging ambulatory pharmacy settings.
Explore the value a strategic partnership can bring in helping take your health system pharmacy further to achieve more.
Use this comprehensive library of resources to find important information on what’s changing with 340B and IRA, when, and why it may matter for your health system pharmacy.
Hear part two of LogiPharma’s interview with McKesson Health Systems President Ammie McAsey.